# POLARIX (NCT03274492)

> A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03274492
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Diffuse Large B-Cell Lymphoma
- Interventions: Polatuzumab Vedotin; Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Vincristine Placebo; Prednisone; Polatuzumab vedotin Placebo
- Enrollment: 1000
- Primary outcome: Progression-Free Survival (PFS) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma

## Commentary we found

- X threads: 104
- YouTube: 100
- Podcasts: 81
- X videos: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=polarix-nct03274492

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03274492", "email": "<work email>"}; the inbox owner confirms by the emailed link.